Format

Send to

Choose Destination
Mod Pathol. 2016 Aug;29(8):854-64. doi: 10.1038/modpathol.2016.75. Epub 2016 May 13.

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.

Author information

1
Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
2
Department of Pathology, Weill Cornell Medical College, New York, NY, USA.
3
Department of Pathology, Stanford University, Stanford, CA, USA.
4
Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
5
Department of Pathology, University of New Mexico, Albuquerque, NM, USA.
6
Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
7
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
8
Department of Pathology, Brigham and Women Hospital, Boston, MA, USA.
9
Department of Pathology, University of Utah, Salt Lake City, UT, USA.
10
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Abstract

The distinction between chronic eosinophilic leukemia, not otherwise specified and idiopathic hypereosinophilic syndrome largely relies on clonality assessment. Prior to the advent of next-generation sequencing, clonality was usually determined by cytogenetic analysis. We applied targeted next-generation sequencing panels designed for myeloid neoplasms to bone marrow specimens from a cohort of idiopathic hypereosinophilic syndrome patients (n=51), and assessed the significance of mutations in conjunction with clinicopathological features. The findings were further compared with those of 17 chronic eosinophilic leukemia, not otherwise specified patients defined by their abnormal cytogenetics and/or increased blasts. Mutations were detected in 14/51 idiopathic hypereosinophilic syndrome patients (idiopathic hypereosinophilic syndrome/next-generation sequencing-positive) (28%), involving single gene in 7 and ≥2 in 7 patients. The more frequently mutated genes included ASXL1 (43%), TET2 (36%), EZH2 (29%), SETBP1 (22%), CBL (14%), and NOTCH1 (14%). Idiopathic hypereosinophilic syndrome/next-generation sequencing-positive patients showed a number of clinical features and bone marrow findings resembling chronic eosinophilic leukemia, not otherwise specified. Chronic eosinophilic leukemia, not otherwise specified patients showed a disease-specific survival of 14.4 months, markedly inferior to idiopathic hypereosinophilic syndrome/next-generation sequencing-negative (P<0.001), but not significantly different from idiopathic hypereosinophilic syndrome/next-generation sequencing-positive (P=0.117). These data suggest that targeted next-generation sequencing helps to establish clonality in a subset of patients with hypereosinophilia that would otherwise be classified as idiopathic hypereosinophilic syndrome. In conjunction with other diagnostic features, mutation data can be used to establish a diagnosis of chronic eosinophilic leukemia, not otherwise specified in patients presenting with hypereosinophilia.

PMID:
27174585
DOI:
10.1038/modpathol.2016.75
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center